According to the report, the global neurological disorder drugs market size surpassed at US$ 78.73 Bn in 2021 and to reach US$ 125.31 billion by 2030 with a CAGR of 5.3% from 2022 to 2030.
According to the report, the global neurological disorder drugs market size surpassed at US$ 78.73 Bn in 2021 and to reach US$ 125.31 billion by 2030 with a CAGR of 5.3% from 2022 to 2030.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/36248
Antiepileptic and anticholinergic drugs are projected to witness exponential growth in demand in the neurological disorder drugs market. Since big pharmaceutical companies are exiting the neurology space, small biotech companies are stepping up to introduce new neurology drugs. However, clinical trials in neuroscience are expensive to run and the success rate is much lower than that of other disease indications. Hence, companies should identify new genes that lead to new pathways in drug delivery for Alzheimer’s and Parkinson’s. Apart from North America, companies should invest in Asia Pacific since the region is projected for exponential growth during the forecast period. Influx of money flow in the field of CNS is one of the key drivers contributing to market growth.
Different types of neurology disorders include epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cerebrovascular diseases, and others. Various drug class to treat neurology disorders are anticholinergic, antiepileptic, antipsychotic, hypnotic & sedative, analgesics, antihypertensive, anticoagulants, and others. Growth of the global neurological disorder drugs market can be attributed to rise in prevalence of neurology diseases among the geriatric population across the globe. North America dominated the global neurological disorder drugs market in 2021 and the trend is anticipated to continue during the forecast period. Increase in awareness about new drugs for treatment and presence of major companies in the region are expected to drive the market in North America. Asia Pacific is likely to be a highly lucrative market for neurological disorder drugs during the forecast period.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 78.73 billion |
| Revenue Forecast by 2030 | USD 125.31 billion |
| Growth rate from 2022 to 2030 | CAGR of 5.3% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Disorder, Drug Class, Distribution Channel, Region |
| Companies Covered | Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Pfizer, Bayer AG, Boehringer Ingelheim GmbH, AstraZeneca, Teva Pharmaceutical Industries, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Amgen, Inc., UCB S.A., Eli Lilly and Company, Biogen |
Investors Address Need for Effective CNS Drugs as Companies Research Neuroscience
Several large-cap pharmaceutical companies are partnering with small biotech companies and academic institutes to innovate in CNS drugs, while regulatory bodies are searching for ways to address the void in effective drug development. Companies in the neurological disorder drugs market are increasing R&D in neuroscience, since the U.S. FDA approved Sage Therapeutics Inc.'s first-of-its-kind postpartum depression therapy Zulresso. With the U.S. being one of the leading countries in North America, the neurological disorder drugs market in the region is anticipated for exponential growth. Moreover, further innovations in CNS drugs.
The field of neuroscience is undergoing a phase of renaissance. This is evident since the FDA stated that organization is witnessing an explosion of new scientific knowledge addressing difficult-to-treat CNS disorders. Investors in the market for neurological disorder drugs are taking note of the FDA’s shifting attitude toward tough-to-treat CNS disorders.
Rise in Prevalence of Neurology Disorders among Geriatric Population and Increase in Therapeutic Treatments to Drive Market
Neurological diseases are more common in older adults, affecting between 5% and 55% of people aged 55 and above. In both high and low income WHO regions, neuropsychiatric conditions are highly important causes of disability. According to the World Health Organization, Europe (11.2%) accounts for majority of the global burden of neurological disorders, while North America accounts for 7.02%. Alzheimer’s Association data indicates that Alzheimer’s disease is the sixth-leading cause of death in the U.S. and one in 10 people aged 65 and older (10%) has Alzheimer’s dementia. An article published in Verdict Media Limited in March 2021 stated that Charity Brain Research UK carries out and supports research into three priority areas in neurology: acquired brain & spinal cord injury, brain tumors, and headache. Brain Research UK invested GBP 1.1 Mn in four new projects that contribute substantially to these areas. Neural stimulation has become the focus of research and treatment in the past few years. There have been profound drug advances in each of its diverse areas.
Innovations in 3D CNS Organoids Revolutionize Neurological Disorder Drugs Market
The Central Nervous System (CNS) drug discovery is largely dependent on traditional approaches related to rodent models or cell-based in vitro models. This practice creates a challenge for drug manufacturers, since species differences between humans and rodents are difficult for the correlation of robust data in neurodevelopmental studies. This explains a modest ~5% CAGR of the neurological disorder drugs market. Hence, companies are advancing in the field of stem cells and 3D CNS organoids, since novel tools have close resemblance to the human brain architecture and functions.
CNS organoids provide innovative opportunities to mimic the human brain physiology and acts as a unique modeling tool for the assessment of normal versus pathological brain. CNS organoids are being highly publicized in the market for neurological disorder drugs for elucidation of mechanisms of neurological disorders. This is evident since the revenue of cerebrovascular disorders is projected to aggressively grow in the market for neurological disorder drugs.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/36248
Cerebrovascular Diseases to Dominate Market
Based on disorder, the global neurological disorder drugs market has been divided into epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cerebrovascular diseases, and others. The cerebrovascular diseases segment dominated the global neurological disorder drugs market in 2021 and the trend is likely to continue during the forecast period, owing to the increasing cases of stroke and intracerebral hemorrhage (ICH).
Antiepileptic to be Promising Drug Class
In terms of drug class, the global neurological disorder drugs market has been classified into anticholinergic, antiepileptic, antipsychotic, hypnotic & sedative, analgesics, antihypertensive, anticoagulants, and others. The antiepileptic segment is expected to expand at the highest CAGR during the forecast period. Rise in cases of epilepsy and increase in research on antiepileptic drugs fuel the growth of the segment.
Retail Pharmacies to be Major Distribution Channel
Based on distribution channel, the global neurological disorder drugs market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies. The retail pharmacies segment dominated the global neurological disorder drugs market in terms of revenue in 2021 and the trend is projected to continue during the forecast period. Increase in the number of neurological disorder drugs being dispensed through retail pharmacies and rise in number of retail pharmacies in developing countries make these pharmacies a major channel of distribution.
North America to Dominate Global Market
The global neurological disorder drugs market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global neurological disorder drugs market in 2021, followed by Europe. North America accounted for major share of the global neurological disorder drugs market in 2021, owing to introduction of new drugs and high prevalence of neurology disorders in countries such as the U.S. The neurological disorder drugs market in Asia Pacific is anticipated to expand at a higher CAGR from 2022 to 2030. Growth of the neurological disorder drugs market in the region can be attributed to high prevalence of neurology diseases and increase in demand for therapeutics.
Related Reports
- Surgical Sutures Market Report 2022-2030 - https://www.visionresearchreports.com/surgical-sutures-market/39144
- Biomarkers Market Report 2022-2030 - https://www.visionresearchreports.com/biomarkers-market/38602
- AI-based Clinical Trials Solution Provider Market Report 2022-2030 - https://www.visionresearchreports.com/ai-based-clinical-trials-solution-provider-market/38345
Leading players analyzed in the report are
- Novartis AG
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd.
- Pfizer
- Bayer AG
- Boehringer Ingelheim GmbH
- AstraZeneca
- Teva Pharmaceutical Industries
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Amgen, Inc.
- UCB S.A.
- Eli Lilly and Company
- Biogen
Market Segmentation
By Disorder
- Epilepsy
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Cerebrovascular Diseases
- Others
By Drug Class
- Anticholinergic
- Antiepileptic
- Antipsychotic
- Hypnotic & Sedatives
- Analgesics
- Antihypertensive
- Anticoagulants
- Others
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/36248
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/